Significant anti-aging effects on heart demonstrated with 50 times higher dosage drug combination.

Update:2023-06-29   

Recently, Professor Shinichiro Imai, a mentor of David Sinclair and a fellow alumnus of Washington University, published a new study on NMN in the official journal of the American Aging Association, "GeroScience". The study suggests that NMN and elamipretide (SS-31) exhibit significant cardiac aging effects at the metabolic level.

heart.jpeg

The heart is the powerhouse of the body's circulatory system, mainly responsible for pushing blood flow through its contracting and relaxing functions to various parts of the body. Cardiac aging is characterized by the declining contractile function of the heart, accompanied by reduced protein abundance and changes in post-translational modifications of proteins. Researchers found that elderly mice treated with NMN and SS-31 showed restoration of certain pathways that had become inactive due to aging, such as a significant recovery in protein abundance in the cellular energy production pathway, resembling the markers of youth. Therefore, it can be seen that the combination of these two substances mainly achieves the reversal of cardiac aging by targeting energy metabolism. The underlying mechanism may be that both substances can combat mitochondrial dysfunction and prevent protein and DNA damage.

Supplementing with NMN can effectively increase the NAD+ levels in the body, activate cellular repair enzymes, and deal with DNA mutation accumulation, thereby avoiding mitochondrial dysfunction. SS-31 indirectly improves the activity of complexes involved in energy production, reduces the production of reactive oxygen species (ROS), and protects against oxidative damage to tissues, thus improving mitochondrial health. In addition, these two substances also exhibit different roles in combating cardiac aging. NMN enhances cardiac contractile ability, while SS-31 enhances relaxation ability. This study provides reference for combating cardiac aging and cardiovascular-related diseases.

Currently, NMN has been very hot and has achieved industrial development. However, it is mainly available in the form of dietary supplements in the health field. However, as research continues to mature, the potential of this substance in disease prevention and improvement of health conditions is gradually being explored. Although most studies are focused on animal experiments, clinical trials in humans are also being conducted. With the efforts of many scientists, NMN is believed to be accepted by the public in China with a legal status. Recently, a company under the Genescapes Group obtained the registration of NMN raw materials from the National Medical Products Administration, signaling the acceptance of this substance by the country.